biostudies-literatureUnknown21(12)Iqbal Z<h4>Objective</h4>BCR-ABL fusion oncogene is the hallmark of chronic myeloid leukemia (CML), causing genomic instability which leads to accumulation of mutations in BCR-ABL as well as other genes. BCR-ABL mutations are the cause of tyrosine kinase inhibitors (TKIs) resistance in CML. Recently, compound BCR-ABL mutations have been reported to resist all FDA approved TKIs. Therefore, finding novel compound BCR-ABL mutations can help and clinically manage CML. Therefore, our objective was to find out novel drug-resistant compound BCR-ABL mutations in CML and carry out their protein modelling studies.<h4>Methodology</h4>Peripheral blood samples were collected from ten imatinib resistant CML patients receiving nilotinib treatment. BCR-ABL transcript mutations were investigated by employing capiAsian Pacific journal of cancer prevention : APJCP3517-3526https://www.ebi.ac.uk/biostudies/studies/S-EPMC8046299biostudies-literatureDiscovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.PMC8046299Akram AMShah IHAbsar MKarim SIqbal JJameel AAlanazi NKhalid AMAljarrah KSabar MFIqbal ZMahmood AAkhtar TKhalid MMirza ZAleem AIqbal MRasool MfalseDiscovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.<h4>Objective</h4>BCR-ABL fusion oncogene is the hallmark of chronic myeloid leukemia (CML), causing genomic instability which leads to accumulation of mutations in BCR-ABL as well as other genes. BCR-ABL mutations are the cause of tyrosine kinase inhibitors (TKIs) resistance in CML. Recently, compound BCR-ABL mutations have been reported to resist all FDA approved TKIs. Therefore, finding novel compound BCR-ABL mutations can help and clinically manage CML. Therefore, our objective was to find out novel drug-resistant compound BCR-ABL mutations in CML and carry out their protein modelling studies.<h4>Methodology</h4>Peripheral blood samples were collected from ten imatinib resistant CML patients receiving nilotinib treatment. BCR-ABL transcript mutations were investigated by employing capi2020-01-01T00:00:00Z2020 Dec2025-04-19T17:04:02.214Z2022-02-09T16:04:09.812ZS-EPMC80462993336944710.31557/APJCP.2020.21.12.3517